Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global hyperglycemia treatment market is expected to reach US$ 500.49 Million in 2023 and is projected to exhibit a CAGR of 12.3% from 2023 to 2033. Researchers from around the world have developed oral drugs and insulin to treat hyperglycemia. As diabetes prevalence increases, new treatment methods are developed, and biotechnology and pharmaceutical investments are increasing, the hyperglycemia treatment market is expected to grow.
Approximately 8.4 million people worldwide suffer from type 1 diabetes (T1D), a disorder characterized by inadequate or no insulin production. A new generation of technology and methods is being used to develop insulins to treat diseases. For example, a protein that mimics the role of insulin has been identified in collaboration with researchers at Lilly, at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia. The discovery could lead to the creation of an oral pill that could replace insulin injections in the future.
Additionally, cryo-electron microscopy (cryo-EM) has allowed researchers to see insulin molecules in great detail with recent breakthroughs in the technique. It is believed that the researchers' discovery will provide insight into the potential for developing novel insulin receptor activators in humans, which may be used for treating diabetes by identifying new treatments to enhance insulin secretion. Furthermore, the FDA has approved Rybelsus (trade name: semaglutide) for treating type 2 diabetes, which is a viable alternative for those who are unwilling or unable to take injections.
Data Points | Key Statistics |
---|---|
Estimated Base Year Value (2022) | US$ 450.9 Million |
Expected Market Value (2023) | US$ 500.49 Million |
Anticipated Forecast Value (2033) | US$ 1,596 Million |
Projected Growth Rate (2023 to 2033) | 12.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to a report from Future Market Insights (FMI), from 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.2%. A significant portion of the market's growth can also be attributed to increasing awareness of diabetes care and management, as well as to technological advancements in medical devices. Additionally, the increase in dietary factors and obesity are driving the hyperglycemia treatment Market.
A variety of clinical trials and studies are currently underway in various parts of the world in order to treat hyperglycemia. For instance, researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, have created the first therapeutic regimen for advanced alveolar soft part sarcomas (ASPS). In recent times, atezolizumab (Tecentriq) has received approval from the USA Food and Drug Administration (FDA) for treating ASPS in adults and children over 2 years who can't be operated on. A rare disease that has been challenging to treat will be greatly impacted by this approval.
As part of its diabetes treatment program, the NIH develops new drugs for patients with type 1 and type 2 diabetes. Researchers found that insulin glargine and liraglutide performed best among four commonly used drugs to treat type 2 diabetes in a large clinical trial. To maintain blood glucose levels in the recommended range. Blood glucose levels are maintained within the recommended range by the USA Food and Drug Administration. Metformin, the first-line drug for treating type 2 diabetes, was added to treatment with all four medications evaluated. In addition to being funded by the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases sponsored the study. The global demand for hyperglycemia treatment is projected to increase at a CAGR of 12.3% during the forecast period between 2023 and 2033, reaching a total of US$ 1,596 Million in 2033.
A Major Boost for New Therapeutic Development Occurred During the Pandemic Crisis
A growing number of technological innovations and artificial intelligence are expected to boost the market for hyperglycemia treatments. A great deal of awareness has been raised over the years and a number of initiatives have been taken to help manage and maintain normal diabetic levels. Different innovative technologies for reversal programs, technological apps, and advancements in drugs have all helped to expand the market.
Various insurance plans and reimbursement policies are also expected to contribute to the growth of the market. There are an increasing number of gadgets and tools in the market now that are being designed and tested to detect the level of sugar present in a person's body before they are placed on the market. For instance, a new method of testing glucose levels has been discovered without constantly pricking the finger. A new glucose sensor that sits beneath the skin's surface has been tested by the Ulsan National Institute of Science and Technology (UNIST). As wearable technologies evolve in the market, it will be easier to monitor blood sugar levels in people with diabetes.
The development of New Therapies and Drugs will drive the Growth of the Market in the Future
Researchers and studies are being conducted to discover new drugs to reverse the diabetic damage caused to millions of people around the world. In addition to viral infections and acute illnesses, new-onset diabetes has been observed after hospital admission. Observing COVID-19-related new-onset diabetes offers a new opportunity for epidemiological and interventional research studies, allowing for a long-term follow-up of these patients. The CoviDIAB Project has been established by an international team of researchers with the aim of collecting data on diabetes caused by COVID-19 that is newly diagnosed. The COVID-19 epidemiology is expected to be further investigated through international collaborative research programs.
Delay in Diagnosis of Hyperglycemia Contributes to Hinder Growth Prospects
Increasing insulin prices and the management of these drugs at home and at the store will further hinder the market's growth. Due to COVID-19, there has been a stagnated rise in hyperglycemia treatment market growth across product segments of this market. The COVID-19 lockdown also disrupted supply chains and led to business interruptions, forcing many biopharmaceutical companies to delay treatment for hyperglycemia until new batches of raw materials became available.
Moreover, after the development, testing, and approval of a hyperglycemia drug, the adoption process begins in the market, posing an obstacle to the growth of the market. Diabetes patients in the USA have a major problem with insulin affordability. Pharmacies and drug stores that stock hyperglycemic medicines face logistical challenges due to the difficulty in finding appropriate distribution channels. A larger patient pool and low awareness about proper treatments and lifestyle may also hamper growth in some countries due to logistical challenges. Taking all these factors into account, the hyperglycemia treatment market will be negatively affected by these factors
As Obesity Issues become more Prevalent, Hyperglycemia Treatment will rise in Frequency
Having a well-established healthcare system and a high awareness of cancer patients, North America is expected to hold 53% of the global healthcare market in 2023. With its high healthcare spending, high diabetes incidence, and neurological disorders, the Americas dominate the global market for treatments for hyperglycemia. Additionally, increased research and development activities and the presence of major companies have contributed to the region's growth.
Diabetes affects 11.3% of Americans, according to the USA Centers for Disease Control and Prevention (CDC). Americans under 65 are particularly affected by insulin costs because regulators and the health care system are largely private. In spite of hopes that diabetes can be treated, the epidemic is spreading in an opposite direction, resulting in longer lifespans and lower quality of life. By 2060, childhood diabetes rates are expected to increase by 60%, according to a recent CDC report.
Around the world, Lantus, a long-acting insulin, is most commonly sold in the USA. Manufacturers of diabetic drugs view it as one of their key markets for expanding global sales. The American market is dominated by Lantus, the most commonly used basal insulin worldwide. Children with diabetes and obesity are increasing in this region, driving the hyperglycemia treatment market to grow.
Changing Economic Conditions and an Increase in Hyperglycemic Patients are furthering Hyperglycemia Treatment
Due to the better distribution of networks among key players in the hyperglycemia treatment market, the European market holds the second largest market share for hyperglycemia treatment. Over the forecast period, it is forecast that the market share for hyperglycemia treatment in Europe is expected to grow to 43% with a CAGR of 4.1%.
As government agencies continue to focus on hyperglycemia and cardiovascular diseases, the treatment of these diseases is becoming increasingly important. Hyperglycemia awareness is further increasing in Europe, which may lead to a rise in the number of devices that are being used to monitor blood sugar levels. In several countries, such as the United Kingdom, France, Germany, and others countries, the rising population contributes to the market's growth. There will be more than 16% growth in the diabetic population in the European region over the next decade. By 2040, diabetes expenditure in Europe will increase to USD 174 billion among patients aged 20-79, according to the International Diabetes Federation (IDF). According to these estimates, diabetes accounts for about 9% of total healthcare expenses in Europe.
German revenues are expected to account for nearly 7% of global markets by 2033. Patients are becoming more aware of hyperglycemia since it is associated with malignancies, the economy is doing better, reimbursement schemes are improving, and hyperglycemia is more common among cancer survivors. In addition, Germany's hyperglycemia treatment market is likely to benefit from favorable regulatory environments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Growth will Increase at a Significant Rate with the Increasing Number of Insulin Therapies
The market for Insulin therapy is expected to grow at a CAGR of 6% from 2023 to 2033. A growing market for insulins is expected to emerge among patients with type 2 diabetes. Recent decades have seen a remarkable advancement in insulin therapy. In recent years, commercial versions of ultra-rapid-acting insulin analogs and ultra-long-acting insulin analogs have been developed. In addition to insulin, there are a lot of other formulations being developed. New insulin therapies are being developed and recent innovations are outlined in this review.
The development of new formulations is another important factor driving the growth of insulin therapy. For instance, Abbott announced the integration of the FreeStyle Libre ® 3 sensors with partners Ypsomed and CamDiab's mylifeTM Loop solution, enabling insulin delivery to be smarter and more automated. In the year 2023, additional European countries will be able to avail of this automated insulin delivery system (AID). This solution continuously monitors a person's glucose levels using CamDiab's CamAPS FX mobile app and Ypsomed's my life TM YpsoPump ®, with accurate 2, real-time data from Abbott's FreeStyle Libre 3 sensor.
Oral Drug Administration Demand for Hyperglycemia Treatment to Gain Traction
Based on the route of administration, the global market is segmented into oral, and topical. Revenue from oral routes of administration is expected to accumulate a market share of 45%. As a result of drug routes for treating hyperglycemia, the market has become much more aware and adaptable.
Oral hypoglycemic drugs are FDA-approved primarily for the treatment of type 2 diabetes. Several modifications to drugs and formulations have been made as a result of technological advancements and innovations over the years. As a result, the market is expected to grow during the analysis period due to the factors mentioned above. There has been a significant increase in the market for oral hyperglycemic treatment due to patient compliance and the convenience of usage of the drugs.
Some of the start-ups in the hyperglycemia treatment market include-
By increasing production and meeting consumer demands, strategic partnerships can help manufacturers boost revenue and market share. Promote new products and technologies to end users so they can benefit from their use. A partnership can increase a company's production capacity by forming a strategic partnership.
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 500.49 Million |
Market Value in 2033 | US$ 1,596 Million |
Growth Rate | CAGR 12.3% |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
The hyperglycemia treatment market CAGR for 2033 is 12.3%.
The market is estimated to reach US$ 1,596 million by 2033.
Novo Nordisk, Sanofi, and Eli Lilly are key market players.
The market is estimated to secure a valuation of US$ 500.49 million in 2023.
The ongoing trends in the market are advanced insulin delivery systems and non-insulin therapies.
1. Executive Summary | Hyperglycemia Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Fluid Replacement 5.3.2. Electrolyte Replacement 5.3.3. Insulin Therapy 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Mode of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Mode of Administration, 2023 to 2033 6.3.1. Topical 6.3.2. Oral 6.4. Y-o-Y Growth Trend Analysis By Mode of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Mode of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals & Clinics 7.3.2. Retail Pharmacy 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East and Africa(MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Treatment 9.2.3. By Mode of Administration 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Mode of Administration 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment 10.2.3. By Mode of Administration 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Mode of Administration 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Treatment 11.2.3. By Mode of Administration 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Mode of Administration 11.3.4. By End User 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Treatment 12.2.3. By Mode of Administration 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Mode of Administration 12.3.4. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Treatment 13.2.3. By Mode of Administration 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By Mode of Administration 13.3.4. By End User 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Treatment 14.2.3. By Mode of Administration 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By Mode of Administration 14.3.4. By End User 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of Middle East and Africa(MEA) 15.2.2. By Treatment 15.2.3. By Mode of Administration 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Treatment 15.3.3. By Mode of Administration 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Treatment 16.1.2.2. By Mode of Administration 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Treatment 16.2.2.2. By Mode of Administration 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Treatment 16.3.2.2. By Mode of Administration 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Treatment 16.4.2.2. By Mode of Administration 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Treatment 16.5.2.2. By Mode of Administration 16.5.2.3. By End User 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Treatment 16.6.2.2. By Mode of Administration 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Treatment 16.7.2.2. By Mode of Administration 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Treatment 16.8.2.2. By Mode of Administration 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Treatment 16.9.2.2. By Mode of Administration 16.9.2.3. By End User 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Treatment 16.10.2.2. By Mode of Administration 16.10.2.3. By End User 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Treatment 16.11.2.2. By Mode of Administration 16.11.2.3. By End User 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Treatment 16.12.2.2. By Mode of Administration 16.12.2.3. By End User 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Treatment 16.13.2.2. By Mode of Administration 16.13.2.3. By End User 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Treatment 16.14.2.2. By Mode of Administration 16.14.2.3. By End User 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Treatment 16.15.2.2. By Mode of Administration 16.15.2.3. By End User 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Treatment 16.16.2.2. By Mode of Administration 16.16.2.3. By End User 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Treatment 16.17.2.2. By Mode of Administration 16.17.2.3. By End User 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Treatment 16.18.2.2. By Mode of Administration 16.18.2.3. By End User 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Treatment 16.19.2.2. By Mode of Administration 16.19.2.3. By End User 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Treatment 16.20.2.2. By Mode of Administration 16.20.2.3. By End User 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Treatment 16.21.2.2. By Mode of Administration 16.21.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Treatment 17.3.3. By Mode of Administration 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Novo Nordisk A/S 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Merck & Company Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Medtronic 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Johnson & Johnson Services, Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Teva Pharmaceuticals Ltd. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Eli Lilly and Company 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Sanofi S.A. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Bayer AG 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Bristol-Myers Squibb. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Abbott 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Mode of Administration, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Mode of Administration, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Mode of Administration, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Mode of Administration, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 19: South Asia Market Value (US$ Million) Forecast by Mode of Administration, 2018 to 2033 Table 20: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 23: East Asia Market Value (US$ Million) Forecast by Mode of Administration, 2018 to 2033 Table 24: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 27: Oceania Market Value (US$ Million) Forecast by Mode of Administration, 2018 to 2033 Table 28: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Mode of Administration, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Mode of Administration, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Mode of Administration, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Mode of Administration, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Mode of Administration, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033 Figure 18: Global Market Attractiveness by Mode of Administration, 2023 to 2033 Figure 19: Global Market Attractiveness by End User, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Mode of Administration, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Mode of Administration, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Mode of Administration, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Mode of Administration, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033 Figure 38: North America Market Attractiveness by Mode of Administration, 2023 to 2033 Figure 39: North America Market Attractiveness by End User, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Mode of Administration, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Mode of Administration, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Mode of Administration, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Mode of Administration, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Mode of Administration, 2023 to 2033 Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Mode of Administration, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by End User, 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Mode of Administration, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Mode of Administration, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Mode of Administration, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 77: Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 78: Europe Market Attractiveness by Mode of Administration, 2023 to 2033 Figure 79: Europe Market Attractiveness by End User, 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 82: South Asia Market Value (US$ Million) by Mode of Administration, 2023 to 2033 Figure 83: South Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 91: South Asia Market Value (US$ Million) Analysis by Mode of Administration, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by Mode of Administration, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Mode of Administration, 2023 to 2033 Figure 94: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 97: South Asia Market Attractiveness by Treatment, 2023 to 2033 Figure 98: South Asia Market Attractiveness by Mode of Administration, 2023 to 2033 Figure 99: South Asia Market Attractiveness by End User, 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 102: East Asia Market Value (US$ Million) by Mode of Administration, 2023 to 2033 Figure 103: East Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 111: East Asia Market Value (US$ Million) Analysis by Mode of Administration, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by Mode of Administration, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Mode of Administration, 2023 to 2033 Figure 114: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 117: East Asia Market Attractiveness by Treatment, 2023 to 2033 Figure 118: East Asia Market Attractiveness by Mode of Administration, 2023 to 2033 Figure 119: East Asia Market Attractiveness by End User, 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 122: Oceania Market Value (US$ Million) by Mode of Administration, 2023 to 2033 Figure 123: Oceania Market Value (US$ Million) by End User, 2023 to 2033 Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 131: Oceania Market Value (US$ Million) Analysis by Mode of Administration, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Mode of Administration, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Mode of Administration, 2023 to 2033 Figure 134: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 137: Oceania Market Attractiveness by Treatment, 2023 to 2033 Figure 138: Oceania Market Attractiveness by Mode of Administration, 2023 to 2033 Figure 139: Oceania Market Attractiveness by End User, 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by Mode of Administration, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by End User, 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by Mode of Administration, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Mode of Administration, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Mode of Administration, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 157: MEA Market Attractiveness by Treatment, 2023 to 2033 Figure 158: MEA Market Attractiveness by Mode of Administration, 2023 to 2033 Figure 159: MEA Market Attractiveness by End User, 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports